Art. -Nr.: HY-15859

Atglistatin

43 Cited Publications

Kundenbewertung

Based on 43 publication(s) in Google Scholar

Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC₅₀ of 0.7 μM in vitro.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.44%
CAS. Nr.: 1469924-27-3
Formel: C₁₇H₂₁N₃O
Molecular Weight:283.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Atglistatin Chemical Structure

CAS. Nr.: 1469924-27-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (43)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC₅₀ of 0.7 μM in vitro.

IC₅₀ & Target

IC50: 0.7 μM (ATGL)^[1]

In Vitro

Atglistatin inhibits Triacylglycerol (TG) hydrolase activity of wild-type white adipose tissue (WAT) in a dose-dependent manner up to 78% at the highest concentration. In comparison to wild-type preparations, TG hydrolase activity in WAT lysates from ATGL-ko animals is reduced by approximately 70% and Atglistatin had only a moderate effect on the residual activity. The combined use of Atglistatin and the hormone-sensitive lipase (HSL) inhibitor Hi 76-0079 leads to an almost complete inhibition (-95%) of TG hydrolase activity of WAT which implicates that most of the non-ATGL activity can be ascribed to HSL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Animals receive Atglistatin dissolved in olive oil by oral gavage. After application, blood and tissues are collected for determination of plasma parameters, tissue Triacylglycerol (TG) levels, and inhibitor concentrations. Time-course experiments revealed that the lipolytic parameters fatty acids (FA) and glycerol are reduced 4 and 8 hours after application and returned to normal after 12 hours. Eight hours after treatment, a dose-dependent decrease is observed in FA and glycerol levels up to 50% and 62%, respectively. Atglistatin also caused a strong reduction in plasma TG levels (-43%) while blood glucose, total cholesterol, ketone bodies, and insulin levels do not significantly change. Dose and time-dependent inhibition of lipolysis is also observed in response to intraperitoneal injection of Atglistatin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1469924-27-3
Appearance Solid
Molecular Weight 283.37
Formel C₁₇H₂₁N₃O
Color White to yellow
SMILES

O=C(NC1=CC(C2=CC=C(N(C)C)C=C2)=CC=C1)N(C)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (43)

All IFCell Imaging/StainingWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. [Abstract]

2025 Sep 26;10(1):315. PMID: 40998786
Cell Metab

Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression. [Abstract]

2025 Sep 24:S1550-4131(25)00385-7. PMID: 40997802
Cell Metab

The mitochondrial calcium uniporter engages UCP1 to form a thermoporter that promotes thermogenesis. [Abstract]

2022 Sep 6;34(9):1325-1341.e6. PMID: 35977541
Cell Mol Immunol

Lipid droplets restrict phagosome formation in antifungal immunity. [Abstract]

2025 Apr 7. PMID: 40195475
Nat Commun

Lipid droplets sequester palmitic acid to disrupt endothelial ciliation and exacerbate atherosclerosis in male mice. [Abstract]

2024 Sep 27;15(1):8273. PMID: 39333556

Atglistatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 27;15(1):8273. [Abstract]

Immunofluorescence images of HAECs treated with ATGL inhibitor (Atglistatin, 10 µM) for 12 h, followed by serum starvation for 48 h (n = 20 fields from 3 independent experiments).
Nat Commun

Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice. [Abstract]

2022 Nov 2;13(1):6577. PMID: 36323699

Atglistatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 2;13(1):6577. [Abstract]

Confocal micrographs showing the LDs (red) and nuclei (blue) in primary hepatocytes isolated from two genotypes treated with atglistatin, an ATGL inhibitor (ATGLi, 10 μM) for 24 h.
Neuron

Rewiring Neuronal Glycerolipid Metabolism Determines the Extent of Axon Regeneration. [Abstract]

2020 Jan 22;105(2):276-292.e5. PMID: 31786011

Atglistatin purchased from MedChemExpress. Usage Cited in: Neuron. 2020 Jan 22;105(2):276-292.e5. [Abstract]

Representative images of DRG neurons in primary cultures treated with DMSO vehicle, Atglistatin (10 μM, 9-11 d). DRG neurites were visualized by Tuj1 staining. Scale bar: 400 μm.

Atglistatin purchased from MedChemExpress. Usage Cited in: Neuron. 2020 Jan 22;105(2):276-292.e5. [Abstract]

Sections of sciatic nerves from WT animals treated with Atglistatin (40mg/kg/day by intraperitoneal injection for consecutive 5 days before injury and 2 days after injury.). Axons are visualized by SCG10 staining. Scale bar: 400 μm.
Autophagy

PRRSV NSP2 hijacks host lipophagy via a LIPE-PNPLA2-AMPK-MTOR axis to promote viral replication. [Abstract]

2026 May 27:1-27. PMID: 42200529
Autophagy

The nuclear receptor ESRRA is a crucial regulator of acute kidney injury through inhibition of the lipophagy-ferroptosis axis. [Abstract]

2026 Apr 27. PMID: 42041131
Autophagy

Lipophagy fuels phosphatidylcholine synthesis for Newcastle disease virus replication. [Abstract]

2026 Mar 11:1-18. PMID: 41810751
Autophagy

Mitochondrial protein COX5B orchestrates antiviral autophagy and apoptosis to restrict SRBSDV propagation in Sogatella furcifera. [Abstract]

2025 Dec 24:1-19. PMID: 41358576
Adv Sci (Weinh)

Seipin-Mediated Lipid Droplet Formation in Cardiomyocytes Ameliorates Cardiac Ischemia/Reperfusion Injury. [Abstract]

2025 Nov 19:e10203. PMID: 41255216

Atglistatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 19:e10203. [Abstract]

Western blotting images of GRP78, Bcl2 and Bax (I, n = 6 each group) in the hearts of WT mice with or without I/R injury (30 min ischemia followed by 24 h reperfusion) with vehicle or Atglistatin treatment (50 mg/kg, i.p., 4 h before I/R surgery)
J Adv Res

Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma. [Abstract]

2025 Aug 8:S2090-1232(25)00596-X. PMID: 40784518
J Biomed Sci

PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation. [Abstract]

2020 Sep 1;27(1):91. PMID: 32873283
Mol Ther

ATGL regulates renal fibrosis by reprogramming lipid metabolism during the transition from AKI to CKD. [Abstract]

2025 Feb 5;33(2):805-822. PMID: 39748508
Diabetologia

Glucolipotoxicity promotes the capacity of the glycerolipid/NEFA cycle supporting the secretory response of pancreatic beta cells. [Abstract]

2022 Apr;65(4):705-720. PMID: 35018486
Cell Death Dis

Lysosomal exocytosis by macrophages as a druggable mechanism for anti-inflammatory clearance of dead adipocytes in adipose tissue. [Abstract]

2025 Dec 23. PMID: 41436477
Cell Death Dis

A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis. [Abstract]

2025 Apr 14;16(1):291. PMID: 40229247
Cell Death Dis

Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease. [Abstract]

2025 Jan 31;16(1):57. PMID: 39890799
Cell Commun Signal

N-acetylaspartate mitigates pro-inflammatory responses in microglial cells by intersecting lipid metabolism and acetylation processes. [Abstract]

2024 Nov 25;22(1):564. PMID: 39587614
EMBO J

Rab2A-mediated Golgi-lipid droplet interactions support very-low-density lipoprotein secretion in hepatocytes. [Abstract]

2024 Dec;43(24):6383-6409. PMID: 39496977
EMBO Mol Med

FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer. [Abstract]

2024 Jul;16(7):1533-1559. PMID: 38926633
Brain Behav Immun

Blockage of ATGL-mediated breakdown of lipid droplets in microglia alleviates neuroinflammatory and behavioural responses to lipopolysaccharides. [Abstract]

2025 Jan:123:315-333. PMID: 39326768
Cell Rep

Adipocyte PI3K links adipostasis with baseline insulin secretion at fasting through an adipoincretin effect. [Abstract]

2024 Apr 23;43(5):114132. PMID: 38656871
Liver Int

Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. [Abstract]

2020 Jun;40(6):1378-1394. PMID: 32145145
Glia

RetSat Knockout Mitigates Hypoxia-Induced Microglial Activation by Enhancing Lipid Droplets Degradation. [Abstract]

2026 Feb;74(2):e70118. PMID: 41388745
Invest Ophthalmol Vis Sci

Atg5-Mediated Lipophagy Induces Ferroptosis in Corneal Epithelial Cells in Dry Eye Disease. [Abstract]

2024 Dec 2;65(14):12. PMID: 39636725
Am J Pathol

Adipose Triglyceride Lipase-Mediated Adipocyte Lipolysis Exacerbates Acute Pancreatitis Severity in Mouse Models and Patients. [Abstract]

2024 Aug;194(8):1494-1510. PMID: 38705384
Biochim Biophys Acta Mol Cell Biol Lipids

Modulation of lipid droplet biogenesis by p38 MAPK and caspase-1 in docosahexaenoic acid-induced EA.hy926 endothelial cell apoptosis. [Abstract]

2025 Aug 22;1870(8):159683. PMID: 40850528
Biochim Biophys Acta Mol Cell Biol Lipids

Lipolysis and lipophagy play individual and interactive roles in regulating triacylglycerol and cholesterol homeostasis and mitochondrial form in zebrafish. [Abstract]

2021 Sep;1866(9):158988. PMID: 34111526
Diabetes Metab Syndr Obes

PEDF Alleviates Diabetic Renal Fibrosis by Degrading Kidney Ectopic Fat Deposition and Inhibiting Metabolic Reprogramming of Renal Tubular Epithelial Cells. [Abstract]

2025 Nov 14:18:4211-4227. PMID: 41262465
Electrophoresis

Towards an Analytical Procedure Control Strategy for the Capillary Zone Electrophoresis Method for Monoclonal Antibodies: Alternatives for ε-Aminocaproic Acid and Triethylenetetramine. [Abstract]

2025 Sep 23. PMID: 40988426
Theriogenology

Salidroside improves bovine embryo quality by mitigating oxidative stress and regulating mitochondrial lipid metabolism. [Abstract]

2025 Nov:247:117570. PMID: 40652734
Fish Physiol Biochem

The reduction of lipid-sourced energy production caused by ATGL inhibition cannot be compensated by activation of HSL, autophagy, and utilization of other nutrients in fish. [Abstract]

2021 Feb;47(1):173-188. PMID: 33245450
Fish Physiol Biochem

Stimulation of glycerol kinase in grass carp preadipocytes by EPA. [Abstract]

2017 Jun;43(3):813-822. PMID: 28058519

Atglistatin purchased from MedChemExpress. Usage Cited in: Fish Physiol Biochem. 2017 Jun;43(3):813-822. [Abstract]

Atglistatin (HY-15859) attenuates the increase in GyK induced by EPA at 12 h. GyK gene expression and enzyme activity after hypertrophic model cells treated with 50 μM HY-15859, 100 μM EPA alone, or both for 12 h.HY-15859 is added 2 h in advance.
Biochem Biophys Res Commun

Cassiaside C alleviates IRI-induced AKI through restoring the expression of ATGL to reduce lipid droplet accumulation. [Abstract]

2026 May 12:822:153940. PMID: 42134150
bioRxiv

2025 Jul 21.
SSRN

2025 May 10.
Research Square Preprint

2024 Oct 18.
Patent

US20240285557A1.
bioRxiv

2024 June 12.
bioRxiv

2023 Dec 1.
bioRxiv

2023 Jul 3.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (352.90 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5290 mL

17.6448 mL

35.2896 mL

5 mM

0.7058 mL

3.5290 mL

7.0579 mL

10 mM

0.3529 mL

1.7645 mL

3.5290 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 6.25 mg/mL (22.06 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (70.58 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

For MTT-based in vitro viability assays, cells are seeded at an initial density of 1×10⁴ cells per well in 96-well plates and cultured under standard conditions for 24 hours. The next day, cells are pretreated with different concentrations of Atglistatin dissolved in DMSO or Cisplatin dissolved in dimethylformamide (DMF) as positive control for two hours. Medium is replaced by an identical fresh medium and incubated again for the indicated time-points. Thereafter cells are incubated for 3 hours with 100 μL Thiazolyl Blue Tetrazolium Bromide (MTT). The resulting violet formazan crystals are dissolved by adding 100 μL of MTT solubilization solution (0.1% NP-40, 4 mM HCl and anhydrous isopropanol). After complete dissolution of the formazan product, absorbance is measured at 595 nm using 690 nm as reference wavelength^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Mice (C57Bl/6J) are used. Atglistatin is administrated orally by gavage in olive oil (200 μL) or by IP injection. For IP administration, we generated Atglistatin hydrochloride by the addition of 25 % HCl resulting in a water soluble compound. For intraperitoneal injection the inhibitor is dried, excess HCl is buffered with Tris base, and Atglistatin is dissolved in PBS containing 0.25 % Cremophor EL (pH 7.1). Atglistatin is administered orally by gavage in olive oil (1.4 mg/mouse). After 8 h tissues are collected and extracted twice using Folch procedure. Combined organic phases are concentrated, reconstituted in 500 μL chloroform and ssubjected to solid phase extraction (SPE). For SPE samples are loaded onto silica columns washed twice with 2 mL of chloroform and Atglistatin is eluted using 3 mL chloroform/methanol (99/1, v/v). Eluted samples are concentrated, dissolved in n-propanol/chloroform/methanol (8/1.3/0.6, v/v/v) and analyzed by UPLC/MS (m/z 284, MH+; SYNAPT G1 qTOF HD mass spectrometer, Waters).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mayer N, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. (2013) Nat Chem Biol. 9(12):785-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5290 mL	17.6448 mL	35.2896 mL	88.2239 mL
	5 mM	0.7058 mL	3.5290 mL	7.0579 mL	17.6448 mL
	10 mM	0.3529 mL	1.7645 mL	3.5290 mL	8.8224 mL
	15 mM	0.2353 mL	1.1763 mL	2.3526 mL	5.8816 mL
	20 mM	0.1764 mL	0.8822 mL	1.7645 mL	4.4112 mL
	25 mM	0.1412 mL	0.7058 mL	1.4116 mL	3.5290 mL
	30 mM	0.1176 mL	0.5882 mL	1.1763 mL	2.9408 mL
	40 mM	0.0882 mL	0.4411 mL	0.8822 mL	2.2056 mL
	50 mM	0.0706 mL	0.3529 mL	0.7058 mL	1.7645 mL
	60 mM	0.0588 mL	0.2941 mL	0.5882 mL	1.4704 mL
	80 mM	0.0441 mL	0.2206 mL	0.4411 mL	1.1028 mL
	100 mM	0.0353 mL	0.1764 mL	0.3529 mL	0.8822 mL

Keywords

Atglistatin

43 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Atglistatin

Metabolism/Protease Compound Library

Anti-diabetic Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Atglistatin

Biologische Aktivität

Chemical Information

Publications (43)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Atglistatin

Metabolism/Protease Compound Library

Anti-diabetic Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Atglistatin

Biologische Aktivität

Chemical Information

Publications (43)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Atglistatin Related Classifications

HY-15859 Related Classifications